• The Author
     
  • The Author
     
  • Paradigm Shift in Vaccines: Our Dengue Vaccine Candidate

    Laurent Lhopitallier, Sanofi
    Sanofi

    Paradigm Shift in Vaccines: Our Dengue Vaccine CandidSanofi Pasteur, the vaccines division of Sanofi, has taken an innovative approach to addressing a disease that affects tropical and subtropical countries, without anticipating a return on investment from high-income countries. For the first time, a new vaccine will have its initial introduction in several middle- and low-income countries – where the need is the greatest.  more[...]

    The Author
     
  • WHO and Sanofi: A Public-Private Partnership to Save Lives

    Dr. Benedict Blayney, Sanofi
    Pierre-Guillaume Harscouët, Sanofi
    Sanofi

    For Sanofi, as a global healthcare partner, improving access to healthcare for the most disadvantaged patients is pivotal to its corporate social responsibility approach. At the core of this commitment is the long-term partnership with the World Health Organization (WHO) to control a group of debilitating infectious diseases, called “neglected tropical diseases,” which affect mostly poor people in developing countries. Since the partnership began, in 2001, more than 20 million people in sub-Saharan Africa have been screened for sleeping sickness, and more than 170,000 patients have received free treatment for what is a fatal disease, if left untreated. This partnership has put the elimination of sleeping sickness within reach – a prospect that was unthinkable a decade ago.  more[...]

    The Author
     
  • The Author
     
  • Corporate Social Responsibility Reporting 2011

    Sanofi

    Corporate Social Responsibility encompasses a broad array of issues. This year, Sanofi's CSR Report addresses 48 topics in it's key areas of Patient, Ethics, People and Planet. Each CSR challenge is important. To avoid a situation where it cannot see the forest for the trees, Sanofi has developed a sound CSR organization and applies sophisticated methods to manage the CSR approach across entire the Group. The CSR approach places the patient at the center of the Group’s business. Woven into the fabric of Sanofi’s values and its strategy, CSR principles provide a vision for the future and foster sustainable growth.  more[...]  login_required

    The Author
     
  • Providing Know-how

    Mireille Cayreyre, Sanofi Aventis

    Accessibility and availability of products are as well as the training of good heath care professionals the key problems in rural areas in Africa. We talked about that with Mireille Cayreyre from Sanofi-Aventis.  more[...]  login_required

    The Author
    Mireille Cayreyre, Sanofi Aventis 
     
  • Attacking a Potential Killer of Children

    Editorial Team

    In 2006, Merck introduced RotaTeq®, its rotavirus vaccine, in the U.S. Merck recognized, however, that this vaccine was most needed in the developing world but that it would be unsustainable to donate it on an ongoing basis – it needed to identify a sustainable business model. Through the Merck-Nicaraguan Ministry of Health RotaTeq® Partnership Merck pledged to donate enough rotavirus vaccine for three birth cohorts of children and funding to introduce the vaccine, improve disease awareness, develop appropriate educational materials, and update the routine vaccination card. Our goal was to demonstrate the feasibility and health benefit of introducing the vaccine in a developing country.  more[...]  login_required

    The Author
    Editorial Team
     
  • Attacking a Potential Killer of Children

    Dr. Barbara J. Kuter, Merck
    Maggie M. Kohn, Merck
    Merck

    In 2006, Merck introduced RotaTeq®, its rotavirus vaccine, in the U.S. Merck recognized, however, that this vaccine was most needed in the developing world but that it would be unsustainable to donate it on an ongoing basis – it needed to identify a sustainable business model. Through the Merck-Nicaraguan Ministry of Health RotaTeq® Partnership Merck pledged to donate enough rotavirus vaccine for three birth cohorts of children and funding to introduce the vaccine, improve disease awareness, develop appropriate educational materials, and update the routine vaccination card. Our goal was to demonstrate the feasibility and health benefit of introducing the vaccine in a developing country.  more[...]

    The Author
     
  • Improving the Future of Epileptic Patients

    Mireille Cayreyre, Sanofi Aventis
    Sanofi

    Epilepsy is not a cause of significant mental impediments. Nevertheless, it is often falsely perceived as a mental disorder in developing countries. Although epilepsy is not fatal, patients who do not receive treatment will experience serious difficulties over their lifetime. In addition to the disease being a handicap in daily life and work, over time, people with epilepsy face social marginalization or even exclusion. In turn, the social group itself is deprived of their economic and social contributions. To address this disease in developing countries, all of these factors need to be taken into account. Sanofi-aventis, as a leader in the global pharmaceutical industry, is thus providing developing countries not only facilitated access to its quality medicines, but also a large number of health services that respond to their specific needs. Epilepsy is not a cause of significant mental impediments. Nevertheless, it is often falsely perceived as a mental disorder in developing countries. Although epilepsy is not fatal, patients who do not receive treatment will experience serious difficulties over their lifetime. In addition to the disease being a handicap in daily life and work, over time, people with epilepsy face social marginalization or even exclusion. In turn, the social group itself is deprived of their economic and social contributions. To address this disease in developing countries, all of these factors need to be taken into account. Sanofi-aventis, as a leader in the global pharmaceutical industry, is thus providing developing countries not only facilitated access to its quality medicines, but also a large number of health services that respond to their specific needs.  more[...]

    The Author
     
  • The Author
     
 
 
 
 

Partners


GCYB

SBA

CSR Manager Logo

 empty

 empty

 

 

 

 

 

Supporters


BMAS

    ESF 

empty


 empty

 

 

 

 

 

About Us // Privacy Policy // Copyright Information // Legal Disclaimer // Contact

Copyright © 2012-2018 macondo publishing GmbH. All rights reserved.
The CSR Academy is an independent learning platform of the macondo publishing group.